Emmanuel Feroldi1, Chitsanu Pancharoen, Pope Kosalaraksa, Kulkanya Chokephaibulkit, Mark Boaz, Claude Meric, Yanee Hutagalung, Alain Bouckenooghe. 1. From the *Sanofi Pasteur Clinical Development Department, Marcy l'Etoile, France; †Chulalongkorn Hospital, Bangkok; ‡Srinagarind Hospital, Khon Kaen University, Khon Kaen; §Siriraj Hospital, Bangkok, Thailand; ¶Sanofi Pasteur Global Clinical Immunology Department, Swiftwater, PA; ‖Sanofi Pasteur Europe New Vaccines Projects, Marcy L'Etoile, France; and **Sanofi Pasteur Clinical Development Department, Singapore.
Abstract
BACKGROUND: The live, attenuated Japanese encephalitis (JE) chimeric virus vaccine (JE-CV) is licensed in Thailand and Australia for prophylaxis of JE in individuals at the age of 12 months. JE-CV has not yet been compared with the SA14-14-2 JE vaccine, which is also licensed in Thailand. METHODS: In this phase 3, observer-blinded trial, 300 children at the age of 9-18 months were randomized 1:1 to receive 1 dose of JE-CV or SA14-14-2. JE neutralizing antibody titers were assessed using PRNT50. The primary endpoint was the noninferiority of seroconversion against JE on Day 28 after JE-CV compared with SA14-14-2, as assessed using the 95% confidence interval of the difference between the groups. Safety and reactogenicity were described in each group using conventional methods, including the reporting of solicited and unsolicited adverse events. RESULTS: The seroconversion rate on Day 28 was 99.2% in each group. Noninferiority was demonstrated as the difference between the JE-CV and SA14-14-2 groups was -0.012 percentage points (95% confidence interval: -3.6 to 3.6), which was above the required -10%. The seroprotection rate remained very high at Month 6 and comparable between groups, but a slight decrease was observed in the JE-CV group between Months 6 and 12. Current recommendations for both vaccines call for a booster dose 12-24 months after primary immunization to maintain high seroprotection rates in the long term. Geometric mean titers (GMTs) on Day 28 after vaccination were 507 (1/dil) in the JE-CV group and 370 (1/dil) in the SA14-14-2 group, decreasing by 4.3-fold and 3.6-fold, respectively, to Month 6 before remaining stable to Month 12 and comparable between groups. Solicited reactions were all reported at lower rates after vaccination with JE-CV compared with SA14-14-2. CONCLUSIONS: A single dose of JE-CV elicited a noninferior immune response compared with SA14-14-2 and had a satisfactory safety profile.
RCT Entities:
BACKGROUND: The live, attenuated Japanese encephalitis (JE) chimeric virus vaccine (JE-CV) is licensed in Thailand and Australia for prophylaxis of JE in individuals at the age of 12 months. JE-CV has not yet been compared with the SA14-14-2 JE vaccine, which is also licensed in Thailand. METHODS: In this phase 3, observer-blinded trial, 300 children at the age of 9-18 months were randomized 1:1 to receive 1 dose of JE-CV or SA14-14-2. JE neutralizing antibody titers were assessed using PRNT50. The primary endpoint was the noninferiority of seroconversion against JE on Day 28 after JE-CV compared with SA14-14-2, as assessed using the 95% confidence interval of the difference between the groups. Safety and reactogenicity were described in each group using conventional methods, including the reporting of solicited and unsolicited adverse events. RESULTS: The seroconversion rate on Day 28 was 99.2% in each group. Noninferiority was demonstrated as the difference between the JE-CV and SA14-14-2 groups was -0.012 percentage points (95% confidence interval: -3.6 to 3.6), which was above the required -10%. The seroprotection rate remained very high at Month 6 and comparable between groups, but a slight decrease was observed in the JE-CV group between Months 6 and 12. Current recommendations for both vaccines call for a booster dose 12-24 months after primary immunization to maintain high seroprotection rates in the long term. Geometric mean titers (GMTs) on Day 28 after vaccination were 507 (1/dil) in the JE-CV group and 370 (1/dil) in the SA14-14-2 group, decreasing by 4.3-fold and 3.6-fold, respectively, to Month 6 before remaining stable to Month 12 and comparable between groups. Solicited reactions were all reported at lower rates after vaccination with JE-CV compared with SA14-14-2. CONCLUSIONS: A single dose of JE-CV elicited a noninferior immune response compared with SA14-14-2 and had a satisfactory safety profile.
Authors: Gregory D Gromowski; Cai-Yen Firestone; José Bustos-Arriaga; Stephen S Whitehead Journal: Am J Trop Med Hyg Date: 2014-10-13 Impact factor: 2.345
Authors: Siraj Ahmed Khan; Sanjeeb Kakati; Prafulla Dutta; Purvita Chowdhury; Jani Borah; Rashmee Topno; Santoshkumar M Jadhav; Pradyumna K Mohapatra; Jagadish Mahanta; Mohan D Gupte Journal: Indian J Med Res Date: 2016-12 Impact factor: 2.375
Authors: Kirsten S Vannice; Susan L Hills; Lauren M Schwartz; Alan D Barrett; James Heffelfinger; Joachim Hombach; G William Letson; Tom Solomon; Anthony A Marfin Journal: NPJ Vaccines Date: 2021-06-15 Impact factor: 7.344
Authors: Dong Soo Kim; Guy Houillon; Gwang Cheon Jang; Sung-Ho Cha; Soo-Han Choi; Jin Lee; Hwang Min Kim; Ji Hong Kim; Jin Han Kang; Jong-Hyun Kim; Ki Hwan Kim; Hee Soo Kim; Joon Bang; Zulaikha Naimi; Valérie Bosch-Castells; Mark Boaz; Alain Bouckenooghe Journal: Hum Vaccin Immunother Date: 2014-11-06 Impact factor: 3.452